December 10, 2019

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(c), Celgene is providing the following information related to the introduction of REBLOZYL® (luspatercept-aamt), approved on November 8, 2019 for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. Pursuant to 18 V.S.A. § 4637(d), Celgene has limited the information reported below to that which is in the public domain or publicly available.

1) There are no marketing or pricing plans in the United States or internationally that are in the public domain or publicly available.

   As with the launch of any new medicine, Celgene actively seeks to educate key stakeholders – including physicians, payers and patients – around the medicine's indication(s), efficacy, and safety profile. Generating this awareness for REBLOZYL® will be a critical component of Celgene's marketing efforts.

   Additionally, as with all of its products, Celgene determined the price of REBLOZYL® with strong consideration of its benefit to patients, health systems and society and in accordance with Celgene's Pricing Principles that focus on access, value, innovation and flexibility.

2) No information regarding the volume of patients who may be prescribed this drug is in the public domain or publicly available.

3) REBLOZYL® was granted a Priority Review by the U.S. Food and Drug Administration (FDA) on June 4, 2019.

4) On August 2, 2011, Celgene made an upfront payment to Acceleron of $25 million as part of a joint development and commercialization agreement for REBLOZYL®. Under this agreement, Acceleron is eligible to receive up to $217 million if specific development, regulatory and commercial milestones are reached for REBLOZYL®.

Sincerely,

James Kilgallon

Executive Director, Pricing and Contracting Strategy